| イスラエル | トルコ | オーストリア | |
| 高密度焦点式超音波焼灼術 | から $15,200 | から $4,000 | から $12,000 |
Ofer Merimsky教授は、骨・軟部腫瘍学の国際的に著名な専門家であり、スーラスキー医療センターにおいて幅広いリーダーシップを担っています。
Dr. Barak Rosenzweig directs the Urological Oncology Service at Sheba Medical Center in Israel. He is a surgeon who has been listed among Israel’s Best Doctors by Forbes. Dr. Rosenzweig specializes in treating tumors of the prostate, kidney, bladder, and testis. He focuses on robotic and minimally invasive cancer surgery to preserve organ function.
High intensity focused ultrasound ablation (HIFU) in Israel uses ultrasound waves to heat and destroy targeted tissue. This non-invasive procedure treats prostate cancer and uterine fibroids with high-frequency energy. Surgeons precisely focus the beam to ablate tumors while sparing surrounding healthy organs and tissue.
Bookimed Expert Insight: While medical HIFU costs $15,200 to $22,500 in Israel, the value lies in specialized techniques like MRgFUS. Centers like Sheba and Rambam use this technology to break tumor barriers for better drug delivery. This helps maximize treatment effectiveness for complex cases that standard ablation alone might not solve.
Patient Consensus: Patients value how focal therapy preserves quality of life, especially for prostate treatment. Many recommend confirming whether sessions are for cancer ablation or cosmetic lifting before booking appointments.
Choosing Israel for HIFU offers access to world-class oncology centers like Sheba Medical Center, ranked 7th worldwide. Patients benefit from advanced MRgFUS technology and surgeons specializing in organ-sparing techniques. This non-invasive approach provides high efficacy for prostate and uterine treatments while reducing recovery times compared to traditional surgery.
Bookimed Expert Insight: Israeli hospitals offer a distinct advantage by integrating MRgFUS with precision genetic testing. While many countries focus on the ablation itself, clinics like Sourasky use Foundation One CDx to ensure HIFU is the most effective biological choice for your specific tumor type. This data-driven approach often leads to higher long-term success rates.
Patient Consensus: Accuracy is the primary concern for most patients, who value the availability of nerve-sparing techniques. Many emphasize confirming the specific clinical team’s experience with robotic-assisted focal therapy before traveling.